指南与共识区域麻醉与超声术前评估与围术期医学

美国区域麻醉与疼痛医学学会第五版抗栓或溶栓治疗患者区域麻醉循证指南

Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (fifth edition).
指南 / 共识 · Reg Anesth Pain Med · 2025-10-17

该指南由美国区域麻醉与疼痛医学学会制定,回顾2018年以来文献,为接受抗栓或溶栓治疗患者行区域麻醉提供循证指导。因出血并发症罕见无法开展大样本随机试验,证据有限时维持「抗出血」保守策略,提出神经阻滞前中断治疗的保守时间,并将抗凝药剂量表述改为「低剂量」和「高剂量」。

要点

  • 证据有限时维持以患者安全为核心的「抗出血」保守策略。
  • 抗凝药剂量改用「低剂量」和「高剂量」表述,便于统一和准确描述。
  • 建议在药物特异性检测有助于指导实践时考虑开具此类检测。

核心结论

  • 区域麻醉相关出血并发症极罕见,但需通过保守中断抗栓治疗时间等措施避免这一灾难性并发症。

研究设计与样本

  • 美国区域麻醉与疼痛医学学会制定的第五版循证指南,回顾2018年以来已发表证据,方法学与既往版本类似但重新组织并大幅精简。

主要发现

  • 因并发症罕见无法开展大型随机对照试验,证据有限处作者维持「抗出血」策略并提出神经阻滞前中断治疗的保守时间。
  • 本版将抗凝药剂量由「预防性」和「治疗性」改为「低剂量」和「高剂量」,以与其他指南一致并更准确描述特定患者特征和适应证下的剂量。
  • 因药物特异性检测可及性增加,指南纳入何时开具这些检测可能有帮助并指导实践的建议。
  • 每条推荐末尾明确标注了与既往版本相比的变化。

关键数值与推荐

  • 抗凝药剂量表述采用「低剂量」和「高剂量」,替代既往的「预防性」和「治疗性」。
  • 证据有限时提出神经阻滞前中断治疗的保守时间建议。
  • 建议在药物特异性检测有助于指导实践时考虑开具此类检测。

临床怎么用

  • 临床医生应查阅早期版本以获取方法学、临床试验、病例系列和药理学的详细描述。
  • 对接受抗栓或溶栓治疗拟行区域麻醉的患者,按本版推荐采用「低剂量」或「高剂量」评估风险并遵循保守中断时间。
  • 关注每条推荐末尾标注的与既往版本的变化,以更新临床实践。

局限性

  • 无法开展评估该罕见并发症的大型随机对照试验,证据有限。
  • 本版大幅精简,方法学、临床试验、病例系列和药理学细节需参考早期版本。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hemorrhagic complications associated with regional anesthesia are extremely rare. The fifth edition of the American Society of Regional Anesthesia and Pain Medicine's Evidence-Based Guidelines on regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy reviews the published evidence since 2018 and provides guidance to help avoid this potentially catastrophic complication.The fifth edition of the American Society of Regional Anesthesia and Pain Medicine's Evidence-Based Guidelines on regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy uses similar methodology as previous editions but is reorganized and significantly condensed. Therefore, the clinicians are encouraged to review the earlier texts for more detailed descriptions of methods, clinical trials, case series and pharmacology. It is impossible to perform large, randomized controlled trials evaluating a complication this rare; therefore, where the evidence is limited, the authors continue to maintain an 'antihemorrhagic' approach focused on patient safety and have proposed conservative times for the interruption of therapy prior to neural blockade. In previous versions, the anticoagulant doses were described as prophylactic and therapeutic. In this version, we will be using 'low dose' and 'high dose,' which will allow us to be consistent with other published guidelines and more accurately describe the dose in the setting of specific patient characteristics and indications. For example, the same 'high' dose may be used in one patient as a treatment for deep venous thrombosis (DVT) and in another patient as prophylaxis for recurrent DVT. Due to the increasing ability to obtain drug-specific assays, we have included suggestions for when ordering these tests may be helpful and guide practice. Like previous editions, at the end of each recommendation the authors have clearly noted how the recommendation has changed from previous editions.

来源:Reg Anesth Pain Med,查看原文。版权归原作者所有。

引用

  1. Kopp SL, Vandermeulen E, McBane RD, et al. Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (fifth edition). Reg Anesth Pain Med. 2025. PMID: 39880411. doi:10.1136/rapm-2024-105766

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。